Australia · Delayed Price · Currency is AUD Invion Company Description
Invion Limited, a clinical-stage life sciences company, researches and develops Photosoft technology for the treatment of cancers, atherosclerosis, and infectious diseases in Australia.
The company develops IVX-PDT, a photosensitising agent to treat a range of cancers, such as skin, prostate, ano-genital, glioblastoma multiforme, lung, and ovarian cancers; and human papilloma virus.
It is also involved in the development of INV043, which is in Phase II clinical trial for the treatment of patients with prostate cancer; and in Phase I/II clinical trial to treat non-melanoma skin cancer, as well as for the treatment of oesophageal cancer.
The company has collaborations with Hudson Institute of Medical Research, Peter MacCallum Cancer Centre, Dr.
I&B Co., Ltd., and Hanlim Pharm Co., Ltd. Invion Limited was incorporated in 2000 and is headquartered in Melbourne, Australia.
| Country | Australia |
| Founded | 2000 |
| Industry | Drug Manufacturers - Specialty & Generic |
| Sector | Healthcare |
| Employees | 4 |
| CEO | Thian Chew |
Contact Details
Address: 385 Bourke Street Melbourne, VIC 3000 Australia | |
| Phone | 61 3 9692 7222 |
| Website | inviongroup.com |
Stock Details
| Ticker Symbol | IVX |
| Exchange | Australian Securities Exchange |
| Fiscal Year | July - June |
| Reporting Currency | AUD |
| ISIN Number | AU000000IVX4 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Thian Chew | Executive Chairman and Chief Executive Officer |
| Melanie Jaye Leydin B.Bus, C.A. | Chief Financial Officer, Company Secretary and Non-Executive Director |
| Dr. Dean Naylor | Head of Intellectual Property Development |